1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
Urothelial Carcinoma- Market Insights, Epidemiology and Market Forecast–2028

Urothelial Carcinoma- Market Insights, Epidemiology and Market Forecast–2028

  • September 2019
  • 254 pages
  • ID: 5816569
  • Format: PDF
  • By Delve Insight

Summary

Table of Contents

‘Urothelial Carcinoma- Market Insights, Epidemiology and Market Forecast–2028’ report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of urothelial carcinoma in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of urothelial carcinoma from 2017 to 2028 segmented by seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2017–2028

Urothelial Carcinoma - Disease Understanding and Treatment Algorithm

Urothelial carcinoma is the invasion of the basement membrane or lamina propria by neoplastic cells of urothelial origin. The WHO has substituted the old-term provisional cell carcinoma with urothelial carcinoma. Invasion is referred to as ‘micro invasion’ when the complexity of invasion is 2 mm or less. The majority of UC occurs in males and approximately has two- to threefold greater incidence as compared to females. The main causative agents of upper tract urothelial carcinoma and urinary bladder cancer include cigarette smoking and work-related exposure, while other factors are more specific to the carcinogenesis of upper tract urothelial carcinoma (i.e., Balkan endemic nephropathy).
The diagnostic workup of urothelial carcinoma requires diagnosis modalities used in BC include imaging (ultrasound, intravenous urography (IVU), computed tomography (CT), and magnetic resonance imaging (MRI)), cystoscopy, biopsy, immunocytology (uCyt+), BTA-TRAK, BTA-STAT analyses, and others. New molecular-based urinary tests are used for reducing or substituting, the endoscopy frequency in BC recurrence patients. The diagnosis requires careful interpretation of examination results in context with the patient’s clinical appearance as well as the exclusion of a broad variety of differential diagnoses.
The Urothelial Carcinoma market report gives the thorough understanding of urothelial carcinoma by including details, such as disease introduction, grading, histological features, staging system, classification, risk factors, pathogenesis, biomarkers, and diagnosis. It also provides treatment algorithms and treatment guidelines for urothelial carcinoma in the US, Europe, and Japan.

Urothelial Carcinoma Epidemiology

According to the American Cancer Society, in 2018 the expected new cases were about 81,190 of bladder cancer with 17,240 deaths. Even with optimal treatment, bladder cancer recurs in more than half of cases and may progress to muscle-invasive BC in up to 20% of these patients. The National Cancer Institute has also suggested a high increase in the number of cases of urothelial carcinoma with an estimated number of 80,470 newly diagnosed cases and 17,670 deaths in 2019.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology scenario of urothelial carcinoma in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and United Kingdom) and Japan from 2017 to 2028 for the following aspects:
• Diagnosed Incident Population of Urothelial Carcinoma
• Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma
• Severity-specific Diagnosed Incident Population of Urothelial Carcinoma
• Age-specific Diagnosed Incident Population of Urothelial Carcinoma
• Gender-specific Diagnosed Incident Population of Urothelial Carcinoma
• Tumor (T) stage-specific Diagnosed Incident Population of Urothelial Carcinoma
• Metastatic stage-specific Diagnosed Incident Population of Urothelial Carcinoma
There are several potential research papers and studies evaluated in order to analyze the overall epidemiology trend in the 7 Major Markets. Few are listed below:
According to a study conducted by Tanaka et al. titled “Diagnosis and Management of Urothelial Carcinoma of the Bladder”, stated that bladder carcinoma is the fourth most common cancer in men and the ninth most common cancer in women in the United States. It is also more common in men, with a male-to-female ratio of 3:1. Approximately 70,000 new cases of bladder carcinoma (52,000 in men and 18,000 in women) and approximately 14,000 deaths were expected in the United States in 2017. The study highlighted through evidence-based analysis that androgens might contribute to the increased incidence of UC of the bladder among men while some studies suggested that estrogens might exert a protective effect in women. In context of urothelial carcinoma subtypes, the natural history of non muscle-invasive disease recurrence is accounted as 50–90% depending on the stage and grade while progression to invasive cancer is accounted as 10–30%.
As per the study conducted by Kabaria et al. titled “Renal cell carcinoma: Links and Risks”, which stated that Kidney and renal pelvis cancer is among the top ten most common cancers in the world. The most frequent type of renal neoplasm is renal cell carcinoma (RCC), which accounts for nearly 85% of all renal malignancies. Urothelial carcinoma of the renal pelvis accounts for the remaining 10%. Also, worldwide, RCC is twice as common in males as females after adjusting for age with >50% of RCC is diagnosed among people aged 55–74 years.
Urothelial Carcinoma Drug Chapters
This segment of the Urothelial Carcinoma report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
To meet the increasing demand for the treatment of Urothelial Carcinoma, companies have shifted their focus toward the development of targeted therapies. Expected launch of potential therapies may increase the market size in the coming years, assisted by an increase in the prevalent population of Urothelial Carcinoma and awareness of the disease. The overall dynamics of Urothelial Carcinoma market is anticipated to change in the coming years owing to the expected launch of emerging therapies of the major key players, such as Eli Lilly and Company, UroGen Pharma, Astellas Pharma/Seattle Genetics, Incyte Corporation, Immunomedics, Nektar Therapeutics/Bristol-Myers Squibb, Rexahn Pharmaceuticals and Acerta Pharma will significantly increase the market during the forecast period (2019–2028).

Urothelial Carcinoma Market Outlook

Urothelial Carcinoma (UC) encompass carcinomas of the bladder, ureters, and renal pelvis. Urothelial cancers make up the majority of cancers for bladder cancer. Urothelial carcinomas (UCs) are the fourth most commonly occurring tumors. Bladder tumors account for 90–95% of UCs and are the most common malignancy of the urinary tract.
Treatment for Urothelial Carcinoma (UC) can be employed in different classes of chemotherapy, immunotherapy, radiation therapy, target specific therapy, and surgical treatment. Chemotherapy majorly forms the first line of treatment mainly comprising platinum-based product wherein cisplatin-based chemotherapy is a chief product in the list of chemotherapeutics. The mainstay for treatment also comprises immunotherapy that helps the patient’s own immune system to recognize and destroy cancer cells. Moreover, radiation therapy is often given along with chemotherapy to help the radiation work well. Transurethral Resection of Bladder Tumor (TURBT) is a gold standard surgical procedure for non-muscle invasive bladder cancer. Several post-chemotherapy surgeries are also performed with the rationale of degeneration of tumor at the initial disease sites.
This segment gives a thorough detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to the analyst, the market of Urothelial Carcinoma in 7MM is expected to change from 2019 to 2028.
Urothelial Carcinoma Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017 to 2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Expected launch of therapies for urothelial carcinoma, such as Ramucirumab (Eli Lilly), UGN-101 (UroGen Pharma), Enfortumab vedotin (Astellas Pharma/Seattle Genetics), Pemigatinib (Incyte Corporation), Sacituzumab govitecan (Immunomedics), NKTR-214 (Nektar Therapeutics/Bristol-Myers Squibb), RX-3117 (Rexahn Pharmaceuticals), and other targeted therapies in the forecast period [2019–2028] will also create a positive impact on the urothelial carcinoma market.

Urothelial Carcinoma Report Insights

• Patient Population
• Therapeutic Approaches
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Urothelial Carcinoma Report Key Strengths

• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition

Urothelial Carcinoma Report Assessment

• Current Treatment Practices
• Unmet Needs
• Market Attractiveness
• Market Drivers and Barriers

Key Benefits

• This report will help to develop Business Strategies by understanding the trends shaping and driving Urothelial Carcinoma market
• Organize sales and marketing efforts by identifying the best opportunities for Urothelial Carcinoma market
• To understand the future market competition in the Urothelial Carcinoma market.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
20% Off

($6250)

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Veronica helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Global Cancer/Tumor Profiling Industry

Global Cancer/Tumor Profiling Industry

  • $ 4950
  • October 2019

Cancer/Tumor Profiling market worldwide is projected to grow by US$5.6 Billion, driven by a compounded growth of 10.4%. Immunoassays, one of the segments analyzed and sized in this study, displays the ...

US and European Interventional Oncology Devices Market Assessment for Breast Cancer, Forecast to 2020

US and European Interventional Oncology Devices Market Assessment for Breast Cancer, Forecast to 2020

  • $ 4950
  • September 2019

The research service provides an overview of the interventional oncology devices market for breast cancer in big five countries in Europe and in the United States. The study provides a four-year forecast ...

Mucin 1 - Pipeline Review, H2 2019

Mucin 1 - Pipeline Review, H2 2019

  • $ 3500
  • August 2019

Mucin 1 - Pipeline Review, H2 2019SummaryMucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial ...


Download Unlimited Documents from Trusted Public Sources

Global Cervical Cancer Statistics - Forecast

  • November 2019
    2 pages
  • Cervical Cancer  

    HPV Testing  

  • World  

    North America  

View report >

Cancer Statistics in the UK

  • November 2019
    2 pages
  • Cancer  

  • United Kingdom  

View report >

Cervical Cancer Statistics and Sexually Transmitted Disease Statistics in the US

  • November 2019
    8 pages
  • Cervical Cancer  

    Sexually Transm...  

  • United States  

    North America  

    Australia  

View report >

Cancer Statistics 15 days ago


ref:plp2019

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on